Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I remember that a buyout was the plan a few years ago (Maza -CEO).
Maza got ILNS with Mindgenix etc... IMO
Daniel Klamer
Associate Professor, Senior Scientist & Entrepreneur
Senior Scientist & Project Leader
Intellect Neurosciences, Inc.
Public Company; 1-10 employees; ILNS; Biotechnologie industry
January 2013 – Present (5 months) New York, New York
Responsible for development of product pipeline
• Developing, managing and communicating the integrated project plans
• Implementing and driving R&D programs towards exit
• Preparing business plans and due diligence documentation
http://www.linkedin.com/pub/daniel-klamer/4/77b/176
2011 10-Q filed on 05/23/2011
I invested in ILNS because Chain is a Genius in his field.
Fact is that this "management" (LoL) burned a lot a lot more than enough money over the years!! Fact is there was no statement from Dr. Chain about his resignation, or from Maza about a bussines strategy, to SHAREHOLDERS.
Fact is we hold 74 patents, viropharma deal, ILNS vs. PFE, and the pipeline...
This following massage is not Off-Topic!
Aesrx and Dr. Swift bought the only valueable xkem patents.
Xkem "shareholders" have the right to get or publicize the informations about the patents and the Sickle Cell developement. This is a delisted ("fka" XKEM) stock, so there is no reason to delete the informations!!
http://marketbrief.com/aesrx-llc/d-a/d-amendment-/2013/5/9/10152904/filing
Many many Thanks to you "deals", our motivator!
Don't give up!
eXaCtLy derrick
ThAnKs PoKeR, pErFeCt! ;)
I got your message
I hOpE aLl sHoRt-sElLeRs wIlL lOsE tHeIr mOnEy hErE!
NOPRESSURE here, next week could be huge for all longs, IMO.
Still hold 2,65M shares and buying a lot more.
ILNS - 74 Patents
120M Viropharma deal!
ILNS vs. PFE!
Huge Pipeline!
Etc.
Best Regards from Europe
Many Thanks to Deals, Poker, Johnny, .....all longs
HoLd sTrOnG mY FrIeNdS!
GLTA
Thanks for your statement
"The patient is sick (ILNS) is there a doctor in the house?"
Delicious!
What or Who is a "LOSER" for you?
Elliot M. Maza
CEO/CFO/Director/Secretary, BioZone Pharmaceuticals, Inc.
Director, Apollo Solar Energy, Inc.
CFO, New Energy Technologies, Inc.
Age: 56
Elliot Maza serves as our Chief Executive Officer, Chief Financial Officer and Secretary. Mr. Maza was appointed as our Interim Chief Executive Officer, Chief Financial Officer and Secretary on May 16, 2011. Mr. Maza was appointed as our Chief Executive Officer on August 2, 2011. On February 24, 2012, the Board of Directors of the Company appointed Elliot Maza as a director of the Company. From May 2006 until the present time, Mr. Maza has served in several management positions at Intellect Neurosciences, Inc., a biotechnology company focused on the development of therapeutics for Alzheimer's disease. Mr. Maza served as the Executive Vice President of Intellect Neurosciences, Inc. from May 2006 to March 2007, as President from March 2007 until October 2011, and as Chief Financial Officer from May 2006 through the present time. Mr. Maza was also appointed to the board of directors of Intellect Neurosciences, Inc. on June 26, 2007. From December 2003 to May 2006, Mr. Maza served as Chief Financial Officer of Emisphere Technologies, Inc., a biopharmaceutical company specializing in oral drug delivery. He was a partner at Ernst and Young, LLP from March 1999 to December 2003. During the period from May 1989 to March 1999, Mr. Maza served as an Associate and subsequently Vice President in the Fixed Income divisions of Goldman Sachs, Inc. and JP Morgan Securities, Inc. Mr. Maza practiced tax and corporate law at Sullivan and Cromwell in New York from September 1985 to April 1989. Mr. Maza has served on the Board of Directors and as Chairman of the Audit Committee of several biotech and pharmaceutical companies. Mr. Maza received his B.A. degree from Touro College in New York and his J.D. degree from the University of Pennsylvania Law School. He is a licensed C.P.A. and a member of the Bar in the states of New York and New Jersey. Mr. Maza was appointed as a director of the Company based on his experience as a senior executive in several biotech and biopharma companies and his positions as chief executive officer and chief financial officer of the Company.
http://www.forbes.com/profile/elliot-m-maza/
Michael Brauser
Co-Chairman/Director, usell.com Inc
Co-Chairman/Director, interCLICK, Inc.
Co-Chairman/Director, ChromaDex Corporation
Age: 55
Michael Brauser has served as Chairman and Co-Chairman (upon the appointment of Mr. Zyman as Executive Chairman on January 27, 2012) since November 18, 2011. Mr. Brauser has been the manager of Marlin Capital Partners, LLC, a private investment company, since 2003. Mr. Brauser served as the Co-Chairman of interclick, inc. from August 2007 until it was acquired by Yahoo, Inc. in December 2011. Between May 2010 and March 2011, Mr. Brauser served on the Board of Directors of Chromadex Corp., a publicly-traded developer of phytochemical and botanical reference standards.
http://www.forbes.com/profile/michael-brauser/
Barry Honig
Co-Chairman/Director, Pershing Gold Corp
Co-Chairman/Director, interCLICK, Inc.
Co-Chairman/Director, ChromaDex Corporation
Age: 40
Barry Honig, Director, was appointed as our Co-Chairman on September 29, 2010 and served as our Chairman from September 2, 2011 to February 9, 2012. Since January 2004, Mr. Honig has been the President of GRQ Consultants, Inc., and is a private investor and consultant to early stage companies and sits on the board of several private companies. Mr. Honig has served as a director of Chromadex Corporation since October 2011 and served as the Co-Chairman of InterCLICK, Inc. from August 2007 through December 2011. Mr. Honig was appointed the co-Chairman of Chromadex Corp. on October 14, 2011.
http://www.forbes.com/profile/barry-honig/
Phillip Frost
Net Worth $2.6 B As of March 2013
Age: 76
Source of Wealth: pharmaceuticals, self-made
Residence: Miami Beach, FL
Country of Citizenship: United States
Education: Medical Doctor, Yeshiva U Albert Einstein College of Medicine; Bachelor of Arts / Science, University of Pennsylvania
Marital Status: Married
Forbes Lists
#554 Billionaires
#194 in United States
#546 in 2012
#190 Forbes 400
Dr. Phillip Frost made his fortune selling drug manufacturer Ivax to Israel's Teva Pharmaceuticals for $7.6 billion in 2005. A former dermatalogy professor, he got his start in pharma in the early 1970s when he took over Key Pharmaceuticals with partner Michael Jaharis to develop generic drugs and veterinary products. They sold out to Schering-Plough in 1986. Frost went on to found Ivax. Today he is chairman of Teva, which moved from Nasdaq to the NYSE earlier this year. He also has stakes in more than a half-dozen firms, including medical device company SafeStitch, and most recently athlete-focused Musclepharm. In May, Frost hosted a $50,000-a-plate dinner for Republican presidential candidate Mitt Romney in his Miami Beach Home. Frost is an active trader, and hold stakes in several public companies. In June, he bought a 45% stake in Israeli vaccine-maker Opko Health.
http://www.forbes.com/profile/phillip-frost/
ViroPharma & Rare Diseases
ViroPharma Proudly Supports HAE Day 2013
MAIDENHEAD, England, May 16, 2013 /PRNewswire/ --
HAE Day takes place on 16 May 2013 and aims to raise awareness of Hereditary Angioedema (HAE)
ViroPharma Incorporated (NASDAQ: VPHM), today announced its support of the second annual international Hereditary Angioedema Day.
HAE Day is coordinated by the HAEi, the International Patient Organization for C1 Inhibitor Deficiency, along with the support of its National Member Organizations and encourages patient organisations from across the globe to organise awareness-raising activities around the theme 'Many faces, one family'. The day aims to raise awareness of HAE among the general public and medical community in order to create an environment with earlier and more accurate diagnosis, improved care and knowledge that HAE patients can lead a normal life.
HAE is a rare, debilitating and potentially life-threatening genetic disorder affecting about 10,000 people across Europe.[1] People living with the condition suffer from recurrent and disabling attacks of swelling that can affect the larynx, abdomen, face, extremities and urogenital tract.
"HAE is a complicated disease that can take many years to diagnose. HAE Day is an exciting event which raises awareness of the condition and helps to ensure patients are diagnosed and treated quickly," said Kristina Broadbelt, Director, Global Advocacy, ViroPharma. "At ViroPharma, we have been working with the HAE community for nearly five years. We are delighted to support this year's HAE Day and we are proud of the difference that we may be able to make in patients' lives."
To learn more about HAE Day events happening in your local area, please visit http://www.haeday.org
ViroPharma provides treatments for patients living with rare diseases including hereditary angioedema, adrenal insufficiency, prolonged, acute, convulsive seizures in children, and Clostridium difficile infection.
As part of its commitment to improving the lives of patients with HAE in Europe, ViroPharma sponsors and funds the Hereditary Angioedema Burden of Illness Study in Europe (HAE-BOIS-Europe), an innovative, patient-centric, multi-country study of the humanistic and economic burden of HAE to address and improve current knowledge gaps surrounding the condition.
ViroPharma Incorporated is based in Exton, Pennsylvania, US, and also has offices in Canada and in eight European countries including Belgium, France, Germany, Italy, Spain, Sweden, Switzerland and the United Kingdom. ViroPharma is continuing to grow its footprint and presence in Europe, and to support this growth, ViroPharma's wholly-owned European subsidiary was set up in 2007, leveraging in Europe the company's expertise in the development and commercialisation of biotechnology products, and in business development.
About Hereditary Angioedema (HAE)
HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, and when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 10,000 people in Europe with HAE, with up to 1,850 cases in the UK.[1]
For more information on HAE, please visit the HAEi's (International Patient Organization for C1 Inhibitor Deficiencies) website at http://www.haei.org/
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercialising novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few, if any, clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, adrenal insufficiency, and Clostridium difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and healthcare professionals we serve.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events, including our ability to continue to deliver solutions that address critical gaps in care for patients living with few, if any, clinical treatment options. There can be no assurance that we will be successful in our efforts to make a difference to patients' lives. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2012 and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission for the periods ended March 31, 2013, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward-looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release
References;
1. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114(3 Suppl):S51-131.. Last accessed on February 6, 2012.
SOURCE ViroPharma Incorporated
http://www.prnewswire.co.uk/news-releases/viropharma-proudly-supports-hae-day---2013-207658921.html
Are you multilingual?
ViroPharma unterstützt den HAE Day 2013 und bringt zusammen mit HAEi Menschen weltweit zum lächeln
München (ots/PRNewswire) -
Der HAE Day am 16. Mai 2013 soll das öffentliche Bewusstsein für das hereditäre Angioödem (HAE) schärfen
Schicken Sie HAE-Betroffenen auf http://www.haeday.org Ihr Lächeln
Die Firma ViroPharma Incorporated gab heute ihre Unterstützung für den zweiten jährlich stattfindenden internationalen HAE Day bekannt. Koordiniert wird der HAE Day von HAEi - der internationalen Organisation von und für Patienten mit C1-Inhibitor-Mangel - mit Unterstützung durch ihre nationalen Mitgliedsorganisationen. Dabei sind Patientenorganisationen in aller Welt aufgerufen, Aufklärungsaktionen rund um das Thema "Viele Gesichter, eine Familie" zu veranstalten. Ziel ist es, das Bewusstsein für HAE sowohl in der breiten Öffentlichkeit als auch in der Ärzteschaft zu schärfen. So soll ein Umfeld geschaffen werden, in dem eine bessere medizinische Behandlung und eine frühzeitigere und gezieltere Diagnose des HAE möglich wird. Die Botschaft lautet: HAE-Patienten können ein gesundes Leben führen.
Bei HAE handelt es sich um eine seltene, stark beeinträchtigende und potentiell lebensbedrohliche genetische Erkrankung, an der etwa 10.000 Menschen in Europa leiden.[1] Die betroffenen Patienten erleiden wiederkehrende und stark beeinträchtigende Schwellungsattacken im Bereich von Kehlkopf, Abdomen, Gesicht, Extremitäten und Urogenitaltrakt.
Die Gefahr, aufgrund einer Schwellung im Kelhkopfbereich zu sterben, ist neunmal höher, wenn die Krankheit nicht erkannt wird; das zeigen die Resultate einer neuen Studie. "Dieses Ergebnis unterstreicht einmal mehr, wie wichtig eine frühzeitige Diagnose und eine rasche, adäquate Therapie für die Überlebenszeit von HAE-Patienten sind," kommentiert einer der Autoren der Studie, Prof. Dr. Konrad Bork von der Uni-Klinik Mainz.
"Das HAE ist eine komplexe Erkrankung und bis zur Stellung der richtigen Diagnose können viele Jahre vergehen. Der HAE Day ist eine vielversprechende Veranstaltung zur Schärfung des Bewusstseins für diese Erkrankung und kann so einen wichtigen Beitrag zur zügigen Diagnosestellung und Therapieeinleitung leisten", so Kristina Broadbelt, Director Global Advocacy. "ViroPharma arbeitet seit fast fünf Jahren mit den HAE-Betroffenen zusammen. Wir freuen uns sehr, den diesjährigen HAE Day unterstützen zu können, und sind stolz darauf, einen positiven Beitrag zum Leben der betroffenen Patienten leisten zu können."
Um HAE-Betroffenen Ihr Lächeln zu schicken oder um mehr über HAE Day-Veranstaltungen in Ihrer Nähe zu erfahren, besuchen Sie bitte die Website http://www.haeday.org.
ViroPharma stellt Therapiemöglichkeiten für Patienten bereit, die mit seltenen Erkrankungen leben, darunter das hereditäre Angioödem, Nebenniereninsuffizienz, länger anhaltende, akute Krampfanfälle bei Kindern und Clostridium difficile-Infektionen.
Im Rahmen seines Engagements für die Verbesserung des Lebens von Patienten mit HAE in Europa hat ViroPharma die Studie HAE-BOIS-Europe (Hereditary Angioedema Burden of Illness Study in Europe) in Auftrag gegeben und finanziert diese. Dabei handelt es sich um eine innovative, patientenzentrierte Mehrländerstudie zu den mit HAE verbundenen menschlichen und volkswirtschaftlichen Belastungen mit dem Ziel, bestehende Wissenslücken in Bezug auf die Erkrankung zu schliessen.
Neben dem Firmensitz in Exton, Pennsylvania (USA), unterhält ViroPharma Incorporated auch Niederlassungen in Kanada sowie in acht Ländern Europas: in Belgien, Frankreich, Deutschland, Italien, Spanien, Schweden, der Schweiz und dem Vereinigten Königreich. Die Bedeutung und Präsenz von ViroPharma in Europa wachsen stetig. Zur Unterstützung dieses Wachstums wurde 2007 eine hundertprozentige Tochtergesellschaft von ViroPharma in Europa gegründet. So soll das Know-how des Unternehmens in der Entwicklung und Vermarktung biotechnologisch hergestellter Präparate und der Erschliessung neuer Geschäftsfelder in Europa voll zum Tragen gebracht werden.
Über das hereditäre Angioödem(HAE)
Bei HAE handelt es sich um eine seltene, schwer beeinträchtigende, lebensbedrohliche genetische Krankheit, die durch einen Mangel des C1-Inhibitors verursacht wird, einem Plasmaprotein im menschlichen Organismus. Diese Krankheit resultiert aus einem Defekt des Gens, das die Synthese des C1-Inhibitors steuert. Der C1-Inhibitor erhält die natürliche Regulation des Kontakt-, Komplement- und Fibrinolysesystems. Unterbleibt dessen steuernder Einfluss, können diese Systeme eine Attacke auslösen oder aufrechterhalten, indem sie den bei HAE-Patienten ohnehin nur in niedrigen Konzentrationen vorkommenden endogenen C1-Inhibitor verbrauchen. Patienten mit C1-Inhibitor-Mangel erleiden wiederkehrende, unvorhersehbare, stark beeinträchtigende und potentiell lebensbedrohliche entzündliche Attacken im Bereich von Larynx, Abdomen, Gesicht, Extremitäten und Urogenitaltrakt. Patienten mit HAE sind rund 20 bis 100 Tage im Jahr arbeitsunfähig. Schätzungen zufolge leiden in Europa mindestens 10.000 Menschen an HAE, in Deutschland weiss man von etwa 1.600 HAE-Patienten.[1],[2]
Weitere Informationen über das HAE erhalten Sie auf der Website der internationalen Patientenorganisation HAEi (International Patient Organization for C1 Inhibitor Deficiencies) unter http://www.haei.org/ [http://www.haei.org ]
Über ViroPharma Incorporated
ViroPharma Incorporated ist ein internationales biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung innovativer Produkte für die fachärztliche Behandlung von Patienten mit Erkrankungen spezialisiert hat, für die es nur wenige oder keine klinischen Behandlungsoptionen gibt, mit dem Ziel, die bestehenden Versorgungslücken zu schliessen. Zu diesen Krankheiten gehören beispielsweise C1-Inhibitor-Mangel, Krampfanfälle bei Kindern und Jugendlichen, Nebenniereninsuffizienz und Infektionen, die durch C. difficile (CDI) verursacht werden. Unser Ziel ist es, Mitarbeitern Karrierechancen zu bieten, neue Versorgungsstandards bei der Behandlung schwerer Krankheiten zu schaffen und internationale Partnerschaften mit Patienten, Fürsprechern und medizinischem Fachpersonal einzugehen.
ViroPharma veröffentlicht regelmässig für Investoren relevante Informationen, unter anderem auch Pressemitteilungen, in den Rubriken "Investor Relations" und "Media" der Unternehmenswebsite http://www.viropharma.com. Investoren können sich hier näher über das Unternehmen und seine geschäftlichen Aktivitäten informieren.
Zukunftsgerichtete Aussagen
Gewisse Angaben in dieser Pressemitteilung enthalten zukunftsgerichtete Aussagen, die einer Reihe von Risiken und Unwägbarkeiten unterliegen. Zukunftsgerichtete Aussagen bringen die gegenwärtigen Erwartungen des Unternehmens oder dessen Vorhersagen hinsichtlich zukünftiger Ereignisse zum Ausdruck, unter anderem im Hinblick auf unser Vermögen, auch weiterhin Lösungen anbieten zu können, welche kritische Versorgungslücken bei Patienten schliessen, für die es wenige oder keine klinischen Behandlungsmöglichkeiten gibt. Es gibt keine Gewähr dafür, dass wir in unserem Bestreben, einen Unterschied im Leben von Patienten zu erzielen, erfolgreich sein werden. Diese und weitere Faktoren, u. a. solche, die in dem auf Formblatt 10-K bei der Securities and Exchange Commission eingereichten Jahresbericht des Unternehmens für das Jahr zum 31. Dezember 2012 und in den auf Formblatt 10-Q eingereichten Quartalsberichten für den Zeitraum zum 31. März 2013, dargelegt werden, könnten dazu führen, dass die zukünftigen Ergebnisse von den in dieser Pressemitteilung ausgedrückten Erwartungen substanziell abweichen. Die zukunftsgerichteten Aussagen in der vorliegenden Pressemitteilung gelten ausschliesslich zum Datum dieser Pressemitteilung und können im Laufe der Zeit veralten. ViroPharma verpflichtet sich nicht zur Aktualisierung von zukunftsgerichteten Aussagen. Es kann nicht gewährleistet werden, dass diese zukunftsgerichteten Aussagen die Einschätzungen des Unternehmens zu einem beliebigen Zeitpunkt nach dem Datum der Veröffentlichung dieser Pressemitteilung darstellen.
Literatur:
1. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114(3 Suppl):S51-131. Letzter Zugriff am 6. Februar 2012.
2. HAE - Hauptsache alle erkennen!; verfügbar unter: http://www.hae-erkennen.de/en_GB/hae-was-ist-das; Letzter Zugriff am 10. Mai 2013
Originaltext: ViroPharma Incorporated Digitale Pressemappe: http://www.presseportal.de/pm/67314 Pressemappe via RSS : http://www.presseportal.de/rss/pm_67314.rss2
Pressekontakt: VIROPHARMA INCORPORATED Ansprechpartner: Emma White (Media Enquiries), PR, Advocacy & Communications Manager Tel.: +44-1628-582732
http://www.finanzen.net/nachricht/aktien/ViroPharma-unterstuetzt-den-HAE-Day-2013-und-bringt-zusammen-mit-HAEi-Menschen-weltweit-zum-laecheln-2436679
What do you expect from ILNS near/long-term future?
Shareholders have to find new motivation like Dr. Chain, IMO.
Thanks NOPRESSURE!
I believe that Dr. Chain got adequate financial resources from institutional investors to in-license Chiesi patent and buyout ILNS. All IMO!
Dr. Chain resigned as CEO
Dr. Chain should knock on Li Ka-shing's door, IMO.
http://www.fiercebiotechit.com/story/hong-kong-billionaire-backs-big-data-effort-biomedicine-oxford-university/2013-05-08
You are absolutely correct.
That's not the end - SEC vs. Blech and Chassman
IMO
Ms. Chassman owns 16.3%
Certain Relationships Involving Margie Chassman and David Blech
Ms. Margie Chassman is one of our founding principal stockholders and is the spouse of Mr. David Blech. Ms. Chassman beneficially owns 16.3% of our common stock, including shares by a trust, for which Ms. Chassman serves as Trustee and of which one of Mr. Blech’s sons is a beneficiary. Ms. Chassman has expressly disclaimed beneficial ownership of certain of the shares that applicable SEC rules deem her to beneficially own. See “Item 12 - Security ownership of certain beneficial owners and management and related stockholder matters.”
http://ir.stockpr.com/intellectns/sec-filings/content/0001144204-12-056105/0001144204-12-056105.pdf
David Blech Article - Hong Kong Standard
http://www.thestandard.com.hk/breaking_news_detail.asp?id=35654&icid=1&d_str=
Yes it was copied
From Yahoo Board
massive upside potential??
To any real longs here (who don't bother to post):
observations:
• ILNS science/IP/patent portfolio is basically sound/solid
• The company is a one-man-band, but so what.
• Company was completely refinanced a few years ago, so the company has no actual debt
- it was all converted to stock
- debt in the balance sheet is only for accounting purposes and to help reduced taxation on future earnings
• $6.5M received from ViroPharma October 2011 (all spent/burned as of latest 10Q)
• company is financed (day-to-day) by purpertual sales of Promisary Notes at 14% interest, carrying "full ratchet protection" (ie. payment of principal+interest in shares at 1 penny each)+millions of warrants at 1/10th penny each
shares outstanding (as of today): 108M
according to my calculations, conversion of all the Notes currently outstanding (principal+interest) converted at 1 penny each, plus all the Warrants = 550M dilution to come.
According to recent 10K, fully diluted shares = 808M
So, there must be some I have missed (not counted).
Longs (historically) have been totally screwed over (that's for sure) by the terms of this totally weird/twisted (and barely legal??) financing.
However, for new-comers/"extreme investors" who might wish to enter this stock now (at 1 penny) I am alone at recognizing a potential thousand-bagger here??
ILNS has solid IP, and Pfizer and J&J are duty bound to pay up. Failure to do is only indicative of such enormous value. By failing to pay, big pharma hopes to drive ILNS bankrupt. So the issues is whether or not big pharma is successful in buying-off the folks at EPO and USPTO. If the bribes fail, intellect is worth (overnight) a billion dollars, even with close to a billions shares outstanding.
Plus, I question the legal status of the "full ratchet" protection...
Are they any serious investors here with any valid inputs (I doubt it, but it's worth asking)..
http://finance.yahoo.com/mbview/threadview/;_ylt=ArzRAbXxxIuTHVpk1GGkSrneAohG;_ylu=X3oDMTFqdDFzcG5iBG1pdANNZXNzYWdlIEJvYXJkcyB3aWRnZXQEcG9zAzIzBHNlYwNNZWRpYU1zZ0JvYXJkcw--;_ylg=X3oDMTFlamZvM2ZlBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDBHBzdGNhdAMEcHQDc2VjdGlvbnM-;_ylv=3?&bn=faee84cc-9764-3fc4-b8fc-3d0136af263c&tid=1367760877979-af7ac9da-d0d5-4cc5-a31a-2f006611a36b&tls=la%2Cd%2C0%2C3
I do not agree because gras(s) is marijuana for the german, swiss and austrian folks. LoL
Good Info, Thx! What is the expected amount of money (2M+ Damage)?
Alzheimer’s Disease Drug Development Deserves Special Government Incentives Including Market Exclusivity
Dec 13 2012
I was invited to speak about vaccines at the 6th Annual Alzheimer’s Drug Discovery Summit in Philadelphia. The meeting provided an excellent forum for a group of academic opinion leaders and industry specialists to hold in-depth discussions regarding recent developments and work being conducted internationally in the field. Unquestionably, 2012 has been an important year that generated critically important clinical data, including the results of the beta amyloid antibody Phase 3 trials and the studies conducted by the Dominantly Inherited Alzheimer’s Network (DIAN) that likely will have a significant impact on the design of future Alzheimer’s clinical trials. At the same time, the fact that the two major sets of Phase 3 clinical trials failed to meet their primary objectives underscored the enormous challenges that lie ahead, including the need to start treatments far earlier, likely when the first symptoms appear or perhaps several years before the onset of symptomatic disease.
The summit was organized by CBI in consultation with Marc Cantillon, MD, Wellness Managements LLC, and former Executive Director, Critical Path Institute Coalition Against Major Diseases (CAMD).
The first day of the conference was chaired by Johan Luthman, PhD, Senior Program Leader Neuroscience R&D, Franchise Integrator at Merck who also spoke about qualification of diagnostic and prognostic biomarkers for AD. Dr. Luthman emphasized the role of biomarkers as essential tools to support diagnosis of early stage AD, offering possibilities to detect prodromal, pre-dementia, stages of the disease and the potential to identify even presymptomatic patients at risk of developing the disease. In addition, Dr. Luthman described how in various natural progression studies, some biomarkers also have been shown to be good predictors of the clinical rate of disease progression (e.g. conversion to dementia), and explained how this link provides opportunities to allowing further stratification of trial populations, as well as evaluate novel therapeutics in populations that previously could not be entered into trials.
The opening address was by John C. Morris, MD, Friedman Distinguished Professor of Neurology, Director Knight Alzheimer’s Disease Research Center, Washington University School of Medicine. As Professor Morris explained, the initial publication of cross-sectional results from DIAN validate the use of Alzheimer’s biomarkers to identify preclinical AD as only mutant carriers demonstrated biomarker abnormalities. Although preliminary, the findings propose an instructive timeline for the pathophysiology of preclinical AD, beginning with elevated CSF Ab that presumably is present at birth but at perhaps 20-25 years prior to onset of symptomatic AD, begins to decline. The DIAN study will provide the infrastructure for randomized, placebo-controlled secondary prevention trials of mechanism-based therapies in dominantly inherited AD. Three drugs have been selected for an initial trial, including gantenerumab (Roche), a monoclonal antibody that binds to all forms of aggregated beta amyloid and currently in prodromal Phase 2/3 trials; solanezumab (Eli Lilly & Co), a monoclonal antibody that binds to soluble forms of beta amyloid, which is to be tested in additional Phase 3 trials; and a BACE inhibitor from Eli Lilly that targets beta amyloid, theoretically reducing the production of beta amyloid and slowing the accumulation of plaques in the brain. Although dominantly inherited AD occurs in only about 1 percent of the population, most experts believe the lessons learned from these trials will have widespread utility and may be applied to testing therapeutics in a much broader population.
J. Michael Ryan, MD, Vice President and Head Neurodegeneration Clinical Science Unit at Novartis moderated a Roundtable Discussion starting with his personal perspective of how recent results will reshape the design and conduct of future AD clinical trials, as well as the allocation of resources devoted to Alzheimer’s research. Dr. Ryan highlighted what had been a recurring theme throughout the conference regarding how the industry will address the major challenges ahead.
I had recommended the organizers of the conference invite John Reppas MD, PhD, Director of Policy at the Neurotechnology Industry Organization (NIO), a global trade association representing companies involved in commercial neurosciences, brain research institutes and patient advocacy groups.
In his address, Dr. Reppas outlined federal policy levers to foster innovation and address public health in AD, especially focused on the NIO-sponsored Neurodegenerative Drug Incentive Initiative, which aims to address the widening gap between prevalence and treatment in neurodegenerative disease conditions, such as AD, Parkinson’s and others that are causing massive public health and economic burdens. Dr. Reppas said the prospects for advancing new therapies to practice are imperiled by the unique length and expense of clinical trials needed to demonstrate safety and efficacy in these diseases. Because of the slowly progressing nature of neurodegenerative diseases, the additional development time consumes both patent protection and defers market entry. It also has led many investors and developers to abandon disease-modifying approaches entirely.
I fully concur with NIO’s belief that the solution to this problem lies in creating a new market exclusivity for sponsors of novel disease-modifying therapeutics that are targeted to neurodegenerative disease, especially AD. The rationale of the NIO initiative follows that of the 1983 Orphan Drug Act, which has since spurred development of new medicines for hundreds of orphan diseases that, otherwise, would not have been addressable given the small market size. A guaranteed market exclusivity period of ten years would be sufficient to tilt the cost-benefit consideration toward continuing drug development for neurodegenerative diseases.
Much has been made about the recent decision of the Obama Administration to push for a $156 million increase in funding for Alzheimer's research over the next two years. Its proponents, especially the Alzheimer’s Association, should be lauded for their commitment to the cause. However, the size of the award is just a drop in the bucket that, in my opinion, will do very little, if anything, to alleviate the situation. Sadly, it underscores a gross lack of understanding on Capitol Hill regarding the needs of the research community -- including industry -- to identify new drugs and advance them through clinical trials as the only way to prevent a catastrophic socio-economic disaster, as more and more Americans are affected by this disease. One wonders how those government officials involved in this decision would feel about the impact of allocating similar funds, barely sufficient to purchase a single stealth bomber, to the overall security of the nation.
I would urge all to support the NIO initiative.
--Daniel Chain, Chairman and CEO, Intellect Neurosciences, Inc.
http://www.intellectns.com/blog
Yep...interesting article
http://commonground.ca/2013/05/decoding-drug-lobbyist-rhetoric/
Read the Blog
http://www.intellectns.com/blog
Have you ever seen the Alpes? :)
An 126,5M agreement for FA...what do you expect for AMD or AD??
Short Volume last Friday - Zero